More on HROW

- Summary
- Chart
- Profile
- Historical

Data

- Earnings (-145.8% Growth)
- Ratings (10.0 Score)

Upcoming Events

- Earnings (8/11/26)

News

- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks
More...

Harrow Health (NQ:HROW)
Delayed: 37.92 -0.53 (1.38%)
Prev. Close $38.45  
Open$39.16 
52 Wk High$ 
52 Wk Low$ 
Day High$39.93 
Day Low$37.36 
P/E N/A  
EPS$ 
Volume332,706 


Jul 27, 2026 07:00 AM Harrow To Report Second Quarter 2026 Financial Results After Market Close on August 10, 2026
Jul 20, 2026 08:00 AM Samsung Bioepis and Harrow share interim data on ranibizumab biosimilar
Jul 20, 2026 08:00 AM Samsung Bioepis and Harrow Present Interim Data from a Large-Scale Post-Marketing Surveillance Study on SB11 (BYOOVIZ® / AMELIVU®), a Biosimilar to Lucentis (ranibizumab), at ASRS 2026
Jul 20, 2026 07:01 AM Harrow presents clinical data on two eye drugs at ASRS meeting
Jul 20, 2026 07:00 AM Harrow Highlights Growing Clinical Evidence Supporting IHEEZO® and BYOOVIZ® at ASRS 2026 Annual Meeting
Jul 1, 2026 07:00 AM Samsung Bioepis relaunches eye disease biosimilar with Harrow in the US
Jul 1, 2026 07:00 AM Harrow launches BYOOVIZ biosimilar for retinal diseases in U.S.
Jul 1, 2026 07:00 AM Harrow Announces Commercial Launch of BYOOVIZ® in the United States
Jul 1, 2026 07:00 AM Samsung Bioepis Relaunches BYOOVIZ® (ranibizumab-nuna) in the United States in Partnership with Harrow
Jun 22, 2026 07:51 PM Form 4 HARROW, INC. For: Jun 18 Filed by: Sternberg Perry J.
View All Articles

Entities mentioned with HROW

View All Entities